Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]CHDI-00485180-R is a Carbon-11 labeled radiopharmaceutical developed as a positron emission tomography (PET) tracer specifically designed to bind to mutant Huntingtin (mHTT) protein aggregates. Developed by the CHDI Foundation, this small molecule tracer is intended for use in clinical research to non-invasively quantify the burden and distribution of mHTT in the brains of individuals with Huntington's disease. By providing a direct measure of the pathological protein, [11C]CHDI-00485180-R serves as a critical biomarker for monitoring disease progression and evaluating the pharmacodynamic effects of huntingtin-lowering therapeutic candidates in clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]CHDI-00485180-R.